Logo

MBOT

Microbot Medical Inc.

MBOT

Microbot Medical Inc. • NASDAQ
$2.42 ▲ 5.68% (+0.13)
Market Cap $110.28 M
52w High $4.67
52w Low $0.93
Dividend Yield 0%
P/E -5.38
Volume 4.03M
Outstanding Shares 45.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.851M ▲ $-3.577M ▼ 0% $-0.074 ▲ $-3.567M ▼
Q2-2025 $0 $3.711M ▲ $-3.5M ▼ 0% $-0.096 ▼ $-3.488M ▼
Q1-2025 $0 $3.021M ▼ $-2.601M ▲ 0% $0.006 ▲ $-3.006M ▲
Q4-2024 $0 $3.404M ▲ $-3.392M ▼ 0% $-0.2 $-3.366M ▼
Q3-2024 $0 $3.3M $-3.215M 0% $-0.2 $-3.277M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $80.158M ▲ $81.76M ▲ $3.536M ▲ $78.224M ▲
Q2-2025 $32.674M ▲ $33.131M ▲ $2.774M ▲ $30.357M ▲
Q1-2025 $30.39M ▲ $30.892M ▲ $1.941M ▼ $28.951M ▲
Q4-2024 $5.47M ▲ $6.031M ▲ $2.501M ▲ $3.53M ▼
Q3-2024 $4.338M $5.208M $1.4M $3.808M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.577M ▼ $-3.841M ▼ $-44.712M ▼ $51.176M ▲ $2.623M ▲ $-3.854M ▼
Q2-2025 $-3.5M ▼ $-2.573M ▲ $-1.309M ▲ $4.752M ▼ $870K ▲ $-2.582M ▲
Q1-2025 $-2.601M ▲ $-2.874M ▼ $-24.83M ▼ $27.806M ▲ $102K ▼ $-2.887M ▼
Q4-2024 $-3.392M ▼ $-1.691M ▲ $1.495M ▲ $2.832M ▲ $2.636M ▲ $-1.698M ▲
Q3-2024 $-3.215M $-2.759M $140K $633K $-1.986M $-2.759M

Five-Year Company Overview

Income Statement

Income Statement Microbot is still a pre-revenue company. It has not yet generated meaningful product sales, so all reported results are driven by research, development, and overhead rather than commercial activity. The company has been running steady operating losses year after year, which is typical for an early-stage medical device developer but means there is no clear line of sight yet to profitability. Earnings per share remain negative, reflecting ongoing spending to build and prove the technology before it can be sold at scale.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base and limited cash relative to the company’s needs. On the positive side, Microbot does not appear to carry financial debt, which reduces interest burdens and refinancing risk. However, the combination of small equity, small assets, and continuing losses suggests that the business has relied, and likely will continue to rely, on new equity or other external funding to support operations until commercial revenues develop.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, which aligns with a company investing in development rather than generating income. Free cash flow is also negative, and there is essentially no meaningful spending on long-term physical assets, implying that most cash goes to people, clinical work, and technology rather than buildings or equipment. In practice, this means the company’s survival and growth depend on its ability to keep raising money until its products can start to pay for themselves.

Competitive Edge

Competitive Edge Microbot is trying to carve out a niche in robotic endovascular surgery with a very different model from traditional, expensive hospital robots. Its disposable, single-use LIBERTY system aims to lower upfront costs, simplify setup, and reduce radiation exposure for physicians, which directly targets well-known pain points in the current market. The company has built a sizable patent portfolio and is an early mover in fully disposable endovascular robotics, which can form a meaningful moat if adoption follows. At the same time, it is competing in a space where large, well-funded players already exist, and its success will ultimately depend on regulatory approvals, clinical acceptance, and the willingness of hospitals and doctors to change established practices.

Innovation and R&D

Innovation and R&D Innovation is the core of Microbot’s story. The LIBERTY system is designed as a disposable, remotely operated robotic platform that could broaden access to robotic procedures by lowering complexity and cost. Beyond that, the Self-Cleaning Shunt aims to tackle shunt failures in hydrocephalus, and the TipCAT platform explores new types of flexible, self-propelled endoscopes. The company also owns FDA-cleared NovaCross microcatheters, which can complement LIBERTY. Recent progress, such as successfully completing a pivotal trial for LIBERTY and submitting to the FDA, shows that R&D is moving from concept toward commercialization. However, timelines, regulatory outcomes, and real-world performance remain key uncertainties.

Summary

Microbot Medical is an early-stage, high-innovation medical device company with no commercial revenues yet and a steady pattern of losses and cash burn. Its financial profile is typical of a development-stage business: light assets, no debt, negative cash flow, and reliance on external capital. The investment case revolves almost entirely around whether its robotic and micro-robotic technologies—especially the disposable LIBERTY system—can clear regulatory hurdles, gain clinical trust, and achieve commercial traction against entrenched competitors. If adoption is strong, the business model could change quickly; if not, the ongoing need to fund R&D and operations without product cash flows is the central risk. Overall, this is a classic “innovation-first, finances-later” story where execution, approvals, and market acceptance are the main variables to watch.

NEWS

November 26, 2025 · 8:30 AM UTC

Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System

Read more

November 5, 2025 · 8:30 AM UTC

Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.

Read more

October 16, 2025 · 8:30 AM UTC

Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting

Read more

October 14, 2025 · 8:30 AM UTC

Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System

Read more

October 7, 2025 · 8:00 AM UTC

Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

Read more